Not medical advice. Talk to your provider before using any peptide.
Full disclaimerPeptide Schedule Research TeamReviewed Apr 20266 Citations
Lixisenatide is a short-acting GLP-1 receptor agonist with four-fold higher receptor binding than native GLP-1. FDA-approved for type 2 diabetes, confirmed cardiovascular-neutral in 6,068 patients. Standalone US product discontinued; available as Soliqua 100/33 with insulin glargine in a fixed-dose combination.
10mcg · Daily
Summary: Add 0mL BAC water to your 10mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
View side effects and safety warnings →
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | Daily |
| Moderate | 20mcg | Daily |
| Aggressive | 20mcg | Daily |
Lixisenatide comes in a pre-filled pen. No vials, no reconstitution, no bacteriostatic water math. The green starter pen delivers 10 mcg per click (14 doses per pen). The burgundy maintenance pen delivers 20 mcg per click (14 doses per pen). Each pen gets discarded 14 days after first use regardless of how many doses remain. Store unused pens in the refrigerator at 2 to 8 degrees Celsius. After the first injection from a pen, keep it at room temperature below 30 degrees Celsius for up to 14 days. Do not freeze. Attach a new needle before each injection and remove it after; storing with a needle attached can cause air bubbles and dose inaccuracy. The timing detail that most people miss: inject within 60 minutes before your first meal of the day. Not after the meal. Not with the meal. Before. The postprandial glucose benefit depends on the gastric emptying delay kicking in before food arrives. If you take oral contraceptives, warfarin, levothyroxine, or any narrow-therapeutic-index drug, take those pills at least one hour before lixisenatide or 11 hours after.
Dosing based on Adlyxin (lixisenatide) FDA Prescribing Information (2024) — 8 published references.View all sources →
Cross-check your Lixisenatide reconstitution math with AI
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Lixisenatide is a short-acting GLP-1 receptor agonist with four-fold higher receptor binding than native GLP-1. FDA-approved for type 2 diabetes, confirmed cardiovascular-neutral in 6,068 patients. Standalone US product discontinued; available as Soliqua 100/33 with insulin glargine in a fixed-dose combination.